Literature DB >> 20665133

Once-daily atomoxetine in the treatment of attention-deficit/hyperactivity disorder in adults.

Ayesha S Lall1, Robert Averbuch.   

Abstract

Entities:  

Year:  2010        PMID： 20665133     DOI： 10.1007/s11920-010-0137-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  3 in total

1.  Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

Authors:  Lenard Adler; Anthony Dietrich; Fred W Reimherr; Leslie V M Taylor; Virginia K Sutton; Rosalie Bakken; Albert J Allen; Douglas Kelsey
Journal:  Ann Clin Psychiatry       Date:  2006 Apr-Jun       Impact factor: 1.567

2.  Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

Authors:  Lenard A Adler; Thomas J Spencer; David W Williams; Rodney J Moore; David Michelson
Journal:  J Atten Disord       Date:  2008-04-30       Impact factor: 3.256

3.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.